Alerta

MULTIOMIC MARKERS OF METABOLIC TRANSITIONS IN AGE-DRIVEN COGNITIVE DECLINE WITH ASSOCIATED INTERVENTION MODALITIES

Resumen de: WO2026019970A1

The disclosure relates to compositions and methods for diagnosing, stratifying, prognosing, treating and preventing and cognitive impairment, including Alzheimer's Disease, based on the identification of disease-associated metabolic transitions.

METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE

Resumen de: CN120731367A

The present invention relates to a method for determining the level of PAM and/or its homoisomers and/or fragments thereof in a bodily fluid or tissue sample using an assay comprising at least one binding agent for conformational epitopes of PAM, and to the use of said method for diagnostic purposes.

アルツハイマー病の無症状期を診断するためのバイオマーカーおよびその使用

Resumen de: CN114981452A

The invention relates to a molecular marker for silent period of Alzheimer's disease. And methods of using the same for diagnosing the silent phase of Alzheimer's disease in a subject, classifying the silent phase of Alzheimer's disease in a subject into different levels of silent phase, predicting the progression of a silent phase of Alzheimer's disease in a subject, and determining an individualized treatment process for a subject suffering from a silent phase of Alzheimer's disease. It also relates to a computer system comprising a trained machine learning algorithm for diagnosing the silent period of Alzheimer's disease in a subject.

METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS

Resumen de: US20260008840A1

Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.

Aβ, pTau 및/또는 tTau를 포함하는 비액 샘플

Resumen de: WO2024235879A1

The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.

OR2AG1 DNA Predicting biomarker for progression of Alzheimers dementia using alteration in DNA methylation of OR2AG1 gene

Nº publicación: KR20260008880A 19/01/2026

Solicitante:

UNIV EWHA IND COLLABORATION [KR]
\uC774\uD654\uC5EC\uC790\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: KR20260008880A

본 발명은 유전자 CpG 부위의 메틸화 수준을 검출함으로써, 알츠하이머병 치매로의 진행 위험성을 예측하기 위한 조성물, 키트 및 방법에 관한 것이다.